<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">TZARTOS, JOHN</style></author><author><style face="normal" font="default" size="100%">PECHLIVANIDOU, MARIA</style></author><author><style face="normal" font="default" size="100%">BOSVELI, DESPOINA</style></author><author><style face="normal" font="default" size="100%">NINOU, ELPINICKIE</style></author><author><style face="normal" font="default" size="100%">YUCEER, HANDE</style></author><author><style face="normal" font="default" size="100%">YALCIN, BEYZANUR</style></author><author><style face="normal" font="default" size="100%">KUCUKALI, CEM ISMAIL</style></author><author><style face="normal" font="default" size="100%">TUZUN, ERDEM</style></author><author><style face="normal" font="default" size="100%">TZARTOS, SOCRATES</style></author><author><style face="normal" font="default" size="100%">TURKDOGAN, DILSAD</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Kelch-like Protein 11 (KLHL11) Antibodies in Children With Seizures of Undetermined Cause</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">351-357</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/invivo.13445</style></doi><volume><style face="normal" font="default" size="100%">38</style></volume><issue><style face="normal" font="default" size="100%">1</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Kelch-like protein 11 (KLHL11)-antibody may be found in paraneoplastic neurological disorders presenting with epileptic seizures. The aim of this study was to investigate the prevalence and clinical significance of KLHL11-antibody in epilepsy. Patients and Methods: Sera of 42 pediatric and 59 adult patients with seizures of undetermined cause were screened using a cell-based assay. Results: KLHL11-antibody was found in three of 168 control patients with paraneoplastic neurological disorders and four pediatric patients (4-8-year-old, 2 boys/2 girls) with seizures of unknown cause presenting with myoclonic-atonic epilepsy, generalized epilepsy or childhood epilepsy with centrotemporal spikes. In these four cases, seizures continued for 2-7 months, responded promptly and favorably to conventional anti-seizure drugs and did not recur in follow-up durations ranging between 2-5 years. Patients had normal brain MRI findings and motor-mental development before and after seizures. KLHL11-antibody was not detected in adult epilepsy patients with undetermined cause, MOG antibody-positive patients and healthy controls. Conclusion: KLHL11-antibody may be detected in pediatric epilepsy patients with a relatively benign disease course.</style></abstract></record></records></xml>